FDA Moves First Needle-Free Anaphylaxis Drug Closer to Reality
A first-of-its-kind rescue drug for severe allergic reactions has cleared a key regulatory hurdle, with the US Food and Drug Administration accepting a resubmitted application for Anaphylm, a sublingual film that could free patients from needle-based autoinjectors. The agency has set a target decision date of March 16, 2027.
Aquestive Therapeutics announced the FDA’s decision on Thursday in its official statement, confirming that the agency had acknowledged the resubmission of the New Drug Application for Anaphylm (dibutepinephrine) as complete and classified it as a Class 2 response. The company resubmitted on September 16 after August results from human-factors and pharmacokinetic studies designed to answer the items raised in the agency’s January 30 Complete Response Letter. If approved, the film would become the first and only oral rescue medication for Type I allergic reactions, including anaphylaxis.
What it would mean for patients
For people living with severe food, drug or insect-sting allergies, the practical appeal is the format: a postage-stamp-sized film, weighing less than an ounce, that dissolves under the tongue on contact — no water, no swallowing, and no needle to drive into a thigh mid-panic attack. The packaging is thinner than an average credit card, designed to ride in a wallet or phone, withstanding rain and sunlight. Many patients and caregivers hesitate with autoinjectors, delaying treatment in the very moments when seconds matter; a familiar, carry-anywhere format is designed to lower that barrier.
The design thinking mirrors a broader push toward smaller, easier medical tools, from a kidney-transplant test’s US commercial push to a blood test entering clinical use. Chief executive Daniel Barber said the acceptance “gives us a clear path forward,” noting that people at risk have had limited treatment options for decades and that the goal is an epinephrine treatment patients “can carry and use confidently, whether at school, at work, or while traveling.” Independent analysis notes that a Class 2 resubmission carries a six-month review clock — putting the decision at March 2027 — and that a $75 million payout to RTW falls due only if approval lands by June 30, 2027.
The road ahead
The company is also preparing its case beyond the United States, with a Canadian submission planned for the final quarter of 2026 and a European filing targeted for early 2027, while commercial launch preparations are already under way. Approval is far from guaranteed — regulators can still ask for more data or disagree with the company’s reading of the results — but the acceptance letter removes the central question that has hung over the drug since January: the review is back on, and there is now a date to watch.
